Allied Market Research

Smart Insulin or Glucose Responsive Insulin Market Expected to Reach $6.17 Billion by 2027


Report Code : A01349

quote The growth of the global smart insulin or glucose responsive insulin market is due to the surge in adoption of technologically advanced products, primarily for diabetes treatment across the globe. quote

Onkar Sumant
Assistant Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       

According to a new report published by Allied Market Research, titled, “smart insulin or glucose responsive insulin market by delivery devices, disease type, and type: opportunity analysis and industry forecast, 2020–2027,” the smart insulin or glucose responsive insulin market size was valued at $2,773.73 million in 2019 and is projected to reach $6,174.30 million by 2027, registering a CAGR of 10.5% from 2020 to 2027. 

Smart insulin is used to deliver insulin into the body of diabetic patients. Smart insulin works according to the blood glucose concentration i.e. higher the blood glucose higher is the concentration of insulin released and lower the blood glucose lower is the concentration of insulin released. Emergence of such healthcare-technologies have addressed high need for better diagnostics as compared to current insulin supply, as it reduces diabetes related stress, decreases the need for regular blood tests, eliminates the need for insulin supplements, and prevents carbohydrate counting. In addition, smart insulin injection can be applied only once a day. Minimal weight gain and reduced risk of hypoglycemia with the help of smart insulin has opened new avenues for its use. Increase in demand for self-injection devices, rise in prevalence of diabetes, and accuracy in dosage delivery of insulin are expected to drive the market growth.

Rise in the number of diabetic patients and benefits of using advanced diabetic devices such as insulin pen, insulin pump, and insulin patches, over conventional products, are expected to boost the growth of the smart insulin or glucose responsive insulin market. Furthermore, increase in disposable income among diabetic patients and technological advancements of next generation diabetic products are anticipated to fuel the market growth. However, lack of awareness, less variability in products, and cost restrains in developing regions are expected to hamper the market growth.

The smart insulin or glucose responsive insulin market is segmented on the basis of delivery devices, disease, type, and region. By delivery devices, the market is bifurcated into smart insulin pen and smart insulin pump. Under the smart insulin pump segment, the market is further classified into tethered insulin pumps and insulin patch pumps. The smart insulin pump is anticipated to grow considerably in the coming future, owing to the facilities provided in these devices such as devices are portable, consisting of a flexible tube for insulin delivery and substitutes the need for multiple injections throughout the day. These devices eliminate the need for long-acting insulin by pumping the short-acting insulin regularly and continuously to better control blood sugar levels.

On the basis of disease segment, the smart insulin or glucose responsive insulin market is divided into type 1 and type 2 diabetes. The prevalence of type 2 diabetes is much more than type I diabetes, the majority products used in the market are either used for both types of diabetes or only for type 2. Type 2 diabetes is the most important contributor toward the market growth. Moreover, as the patients suffering from type 2 diabetes are increasing at a higher rate, it is anticipated to be the fastest growing segment of the market

By type, the market is divided into rapid-acting, intermediate-acting, long-acting, short-acting and pre-mixed type. The rapid acting segment is anticipated to grow at a significant rate during the forecast period. Rapid-acting insulin is one of the fastest acting insulin that start working in 15 minutes of its use. The activity of this insulin is supposed to last for 5 hours. Some of the rapid-acting insulin available in the market are Humalog, Fiasp and NovoRapid, and Apidra. Rapid-acting insulin are usually prefer in pumps that delivers little amounts of insulin into the body every few minutes.

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America holds a dominant share in the global Smart Insulin or Glucose Responsive Insulin market, because well-developed supply-side infrastructure, rapid acceptance of innovative technologies, and adequate reimbursements (as compared to other geographies) have fueled the growth of the North American smart insulin or glucose responsive insulin market.

Key Findings Of The Study 

  • By delivery devices, the smart insulin pump segment occupied 96.9% share of the smart insulin or glucose responsive insulin market in 2019.
  • By disease type, the type 2 disease segment is anticipated to grow with the highest CAGR throughout the forecast period.
  • By type, the rapid acting segment occupied 32.8% share of the smart insulin or glucose responsive insulin market in 2019.
  • By region, North America is anticipated to experience growth at 39.5% during the forecast period

Prominent key players operating in the market include CeQur, Diamesco Co, Eli lily and Company, Insulet Corporation, Medtronic, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Sanofi and Zealand Pharma.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975



For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at


First time buyer?
Check offers and discount on this report
To get this report

Click Here

quote Smart Insulin or Glucose Responsive Insulin Market by Delivery Devices (Smart Insulin Pen and Smart Insulin Pump), Disease, (Type 1 Diabetes and Type 2 Diabetes), and Type (Rapid Acting, Intermediate Acting, Long Acting, Short Acting, and Premixed Type): Global Opportunity Analysis and Industry Forecast, 2019–2027 quote

View Report
Avenue Video Loading...

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.


Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers


Featured Readings


Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

Get Industry Data Alerts

Buy Full Version
"Smart Insulin or Glucose Responsive Insulin Market"
Purchase Enquiry